Fri, 21st May 2021 21:18
May 21 (Reuters) - AstraZeneca's COVID-19 vaccine
was only slightly less effective against the variant first found
in India than the strain identified in Kent, the company's Chief
Executive Officer Pascal Soriot said in an interview with
Financial Times on Friday.
He added the company is in talks with governments, including
the United Kingdom, about new contracts for booster doses.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Chris
Reese)
(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...
(Correcting company name in headline)
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
Astrazeneca (AZN)